Authors
Reddy Sreekanth Vootukuri, Katarzyna Dyjach, Youssef Khalil, Joanna Toporowska, Sam Rowley, Charalambos Demetriou, Nicholas D E Greene, Kyle O'Sullivan, Barbara Plecko, Sidney M Gospe, Alex Mackensie, Izabella A Pena, Peter T Clayton, Julien Baruteau, Paul Gissen, Haiyan Zhou, Philippa B Mills
Published in
Science translational medicine. Volume 18. Issue 876. Pages eaei9706. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
α-Aminoadipic semialdehyde synthase (AASS) catalyzes the first two steps of lysine catabolism. Inherited metabolic disorders affecting enzymes downstream of AASS, including α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) deficiency, which causes pyridoxine-dependent epilepsy, and glutaric aciduria type I, cause accumulation of potentially neurotoxic lysine-derived metabolites. Current therapies incompletely prevent metabolite accumulation and neurological sequelae. We evaluated whether hepatic AASS silencing could reduce conversion of lysine into downstream metabolites. Antisense oligonucleotides and small interfering RNAs targeting AASS reduced disease-associated metabolites in patient-derived cells from individuals with ALDH7A1 deficiency and glutaric aciduria type I. Hepatocyte-selective delivery, enabled by N-acetylgalactosamine conjugation, achieved >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, with sustained protein suppression and reduced accumulation of downstream lysine-derived metabolites. These findings support further evaluation of oligonucleotide-mediated AASS silencing, including liver-directed delivery, as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.
PMID:
43050502
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0